PF-05221304 是一种具有口服活性的肝脏靶向乙酰辅酶A羧化酶 (ACC) 抑制剂，ACC 是脂肪酸合成的限速酶。

PF-05221304 is an orally active, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), a rate-limiting enzymes for fatty acid synthesis.

PF-05221304 blocked polarization of human T cells to proinflammatory but not anti-inflammatory T cells, and suppressed activation of primary human stellate cells to myofibroblasts in vitro, showing direct effects on inflammation and fibrogenesis[1].

PF-05221304 reduced markers of inflammation and fibrosis in the diethylnitrosamine chemical-induced liver injury model and the choline-deficient, high-fat-fed rat model[1].

1370448-25-1

C28H30N4O5

502.571

R 6238,;STAT5 Inhibitor III;NSC 170984;Clesacostat

DMSO:95mg/ml(189.03mM)
ethanol:5mg/ml(9.95mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years